PAFOLACIANINE SODIUM

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C61H63N9O17S4.4Na
Molecular Weight	1414.422
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	3
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].[Na+].[Na+].[Na+].CC1(C)\C(=C/C=C2\CCCC(\C=C\C3=[N+](CCCCS([O-])(=O)=O)C4=CC=C(C=C4C3(C)C)S([O-])(=O)=O)=C2OC5=CC=C(C[C@H](NC(=O)C6=CC=C(NCC7=NC8=C(N=C7)N=C(N)NC8=O)C=C6)C([O-])=O)C=C5)N(CCCCS([O-])(=O)=O)C9=CC=C(C=C19)S([O-])(=O)=O

InChI

InChIKey=LRVBSDMJFVZFHH-NFVAJSDSSA-J

InChI=1S/C61H67N9O17S4.4Na/c1-60(2)46-33-44(90(81,82)83)22-24-49(46)69(28-5-7-30-88(75,76)77)51(60)26-16-38-10-9-11-39(17-27-52-61(3,4)47-34-45(91(84,85)86)23-25-50(47)70(52)29-6-8-31-89(78,79)80)54(38)87-43-20-12-37(13-21-43)32-48(58(73)74)66-56(71)40-14-18-41(19-15-40)63-35-42-36-64-55-53(65-42)57(72)68-59(62)67-55;;;;/h12-27,33-34,36,48H,5-11,28-32,35H2,1-4H3,(H9-,62,63,64,66,67,68,71,72,73,74,75,76,77,78,79,80,81,82,83,84,85,86);;;;/q;4*+1/p-4/t48-;;;;/m0..../s1

HIDE SMILES / InChI

Molecular Formula	Na
Molecular Weight	22.98976928
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C61H63N9O17S4
Molecular Weight	1322.463
Charge	-4
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	3
Optical Activity	UNSPECIFIED

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214907s000lbl.pdf | https://pubmed.ncbi.nlm.nih.gov/36361630 | http://www.checkorphan.org/news/first-patient-treated-in-pivotal-phase-3-trial-to-evaluate-otl38-in-the-detection-of-ovarian-cancer | https://www.purdue.edu/newsroom/releases/2016/Q4/molecule-that-lights-up-cancer-accelerating-toward-fda-approval.html

OTL-38 (OTL-0038, Pafolacianine), a fluorescent-labelled folate receptor-α (FRα) targeted imaging agent that accumulates in vivo in tumor cells expressing FR. In 2014, the OTL-38 molecule was granted orphan drug status which can be given to the maker of a drug that treats rare conditions or diseases and offers protection from competition for a period of time. OTL-38 under the brand name Cytalux was approved by the U.S. Food and Drug Administration (FDA) on 29 November 2021, as an additional approach that can be used to identify malignant lesions and to ensure the total resection of the tumors in ovarian cancer patients. Cytalux is a fluorescent drug that targets folate receptor which may be overexpressed in ovarian cancer. Pafolacianine binds to FR-expressing cancer cells with ~1 nM affinity, internalizes via receptor mediated endocytosis, and concentrates in FR-positive cancer tissues. Pafolacianine absorbs light in the near-infrared region within a range of 760 nm to 785 nm with peak absorption of 776 nm and emits fluorescence within a range of 790 nm to 815 nm with a peak emission of 796 nm.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Folate receptor alpha 2 Target ID: P15328 Gene ID: 2348.0 Gene Symbol: FOLR1 Target Organism: Homo sapiens (Human) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214907s000lbl.pdf\|https://pubmed.ncbi.nlm.nih.gov/30296376			0.8 null [Other]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Ovarian cancer 160 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214907s000lbl.pdf	Diagnostic		Approved 8583	CYTALUX Approved Use CYTALUX is an optical imaging agent indicated in adult patients with ovarian cancer as an adjunct for intraoperative identification of malignant lesions. Launch Date 2021

C_max

Value	Dose	Analyte	Population
59.1 ng/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214907s000lbl.pdf#page=7	3.2 mg single, intravenous dose: 3.2 mg route of administration: Intravenous experiment type: SINGLE co-administered:	OTL-38 plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
61.7 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27306792/	0.025 mg/kg single, intravenous dose: 0.025 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	OTL-38 plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
173 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27306792/	0.05 mg/kg single, intravenous dose: 0.05 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	OTL-38 plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
458 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27306792/	0.1 mg/kg single, intravenous dose: 0.1 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	OTL-38 plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
606 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27306792/	0.2 mg/kg single, intravenous dose: 0.2 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	OTL-38 plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

AUC

Value	Dose	Analyte	Population
63.6 ng × h/mL DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214907s000lbl.pdf#page=7	3.2 mg single, intravenous dose: 3.2 mg route of administration: Intravenous experiment type: SINGLE co-administered:	OTL-38 plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
59.2 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27306792/	0.025 mg/kg single, intravenous dose: 0.025 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	OTL-38 plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
250 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27306792/	0.05 mg/kg single, intravenous dose: 0.05 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	OTL-38 plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
830 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27306792/	0.1 mg/kg single, intravenous dose: 0.1 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	OTL-38 plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN
1250 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27306792/	0.2 mg/kg single, intravenous dose: 0.2 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:	OTL-38 plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
0.44 h DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214907s000lbl.pdf#page=7	3.2 mg single, intravenous dose: 3.2 mg route of administration: Intravenous experiment type: SINGLE co-administered:		OTL-38 plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN
2.6 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/27306792/	0.2 mg/kg single, intravenous dose: 0.2 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered:		OTL-38 plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
0.2 mg/kg single, intravenous Highest studied dose Dose: 0.2 mg/kg Route: intravenous Route: single Dose: 0.2 mg/kg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: unknown Food Status: UNKNOWN Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf	Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf
0.025 mg/kg single, intravenous Recommended Dose: 0.025 mg/kg Route: intravenous Route: single Dose: 0.025 mg/kg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf	Disc. AE: Vomiting, Nausea... AEs leading to discontinuation/dose reduction: Vomiting (2 pt) Nausea (3 patients) Hypersensitivity (2 patients) Rash (1 pt) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf
0.025 mg/kg single, intravenous Recommended Dose: 0.025 mg/kg Route: intravenous Route: single Dose: 0.025 mg/kg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf	Disc. AE: AE, AE... AEs leading to discontinuation/dose reduction: AE (13 patients) AE (41 patient) Vomiting (<= 2, 2 patients) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf

AEs

AE	Significance	Dose	Population
Rash	1 pt Disc. AE	0.025 mg/kg single, intravenous Recommended Dose: 0.025 mg/kg Route: intravenous Route: single Dose: 0.025 mg/kg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf
Hypersensitivity	2 patients Disc. AE	0.025 mg/kg single, intravenous Recommended Dose: 0.025 mg/kg Route: intravenous Route: single Dose: 0.025 mg/kg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf
Vomiting	2 pt Disc. AE	0.025 mg/kg single, intravenous Recommended Dose: 0.025 mg/kg Route: intravenous Route: single Dose: 0.025 mg/kg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf
Nausea	3 patients Disc. AE	0.025 mg/kg single, intravenous Recommended Dose: 0.025 mg/kg Route: intravenous Route: single Dose: 0.025 mg/kg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: F Food Status: UNKNOWN Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf
AE	13 patients Disc. AE	0.025 mg/kg single, intravenous Recommended Dose: 0.025 mg/kg Route: intravenous Route: single Dose: 0.025 mg/kg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf
AE	41 patient Disc. AE	0.025 mg/kg single, intravenous Recommended Dose: 0.025 mg/kg Route: intravenous Route: single Dose: 0.025 mg/kg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf
Vomiting	<= 2, 2 patients Disc. AE	0.025 mg/kg single, intravenous Recommended Dose: 0.025 mg/kg Route: intravenous Route: single Dose: 0.025 mg/kg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
MATE2-K 77 OATP1B1 1079 MATE1 415 P-gp 1741 CYP1A2 2153 CYP2B6 926 CYP2C8 1057 OAT3 747 CYP2C19 2057 OATP1B3 961 BCRP 910 OCT2 779 UGT1A1 246 CYP3A5 136 OAT1 725 BSEP 550	OATP1B3 435 OATP1B1 503 OCT2 434 P-gp 2052 OAT1 395 BCRP 697 MATE1 182 UGT 219 OAT3 391 CYP 303 MATE2-K 33

Drug as perpetrator

Target	Modality	Activity
BCRP 985	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf#page=63 Page: 63.0	likely
BSEP 554	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf#page=63 Page: 63.0	likely
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf#page=63 Page: 63.0	likely
CYP2B6 1160	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf#page=63 Page: 63.0	likely
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf#page=63 Page: 63.0	likely
CYP2C8 1117	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf#page=63 Page: 63.0	likely
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf#page=63 Page: 63.0	likely
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf#page=63 Page: 63.0	likely
CYP3A4 2633	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf#page=63 Page: 63.0	likely
CYP3A5 201	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf#page=63 Page: 63.0	likely
MATE1 416	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf#page=63 Page: 63.0	likely
MATE2-K 77	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf#page=63 Page: 63.0	likely
OAT1 730	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf#page=63 Page: 63.0	likely
OAT3 749	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf#page=63 Page: 63.0	likely
OATP1B1 1095	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf#page=63 Page: 63.0	likely
OATP1B3 970	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf#page=63 Page: 63.0	likely
OCT2 782	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf#page=63 Page: 63.0	likely
P-gp 1932	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf#page=63 Page: 63.0	likely
UGT1A1 303	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf#page=68 Page: 68.0	no

Drug as victim

Target	Modality	Activity
MATE1 182	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf#page=39 Page: 39.0	inconclusive
MATE2-K 33	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf#page=39 Page: 39.0	inconclusive
BCRP 697	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf#page=39 Page: 39.0	no
CYP 303	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf#page=60 Page: 60 \| 61	no
OAT3 391	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf#page=39 Page: 39.0	no
OCT2 434	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf#page=39 Page: 39.0	no
P-gp 2052	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf#page=39 Page: 39.0	no
UGT 219	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf#page=60 Page: 60.0	no
OAT1 395	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf#page=39 Page: 39.0	yes
OATP1B1 503	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf#page=39 Page: 39.0	yes
OATP1B3 435	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf#page=39 Page: 39.0	yes

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214907Orig1s000MultidisciplineR.pdf#page=37 Page: 31 \| 37

PubMed

Title	Date	PubMed
Intraoperative Tumor Detection Using Pafolacianine.	2022-10-25	36361630
Folate receptor-α targeted near-infrared fluorescence imaging in high-risk endometrial cancer patients: a tissue microarray and clinical feasibility study.	2018-01-02	29416655
Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors: a patent evaluation of US20160011199A1.	2016-11	27685539

Patents

Sample Use Guides

In Vivo Use Guide

Recommended dosage of CYTALUX is 0.025 mg/kg administered intravenously over 60 minutes 1 hour to 9 hours prior to surgery.

Route of Administration: Intravenous

In Vitro Use Guide

Pafolacianine binds to FR-expressing cancer cells with ~1 nM affinity.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 23:17:38 GMT 2025` Edited by `admin` on `Mon Mar 31 23:17:38 GMT 2025`
Record UNII	4HUF3V875C
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PAFOLACIANINE SODIUM

Official Name

English

3H-INDOLIUM, 2-(2-(2-(4-((2S)-2-((4-(((2-AMINO-3,4-DIHYDRO-4-OXO-6-PTERIDINYL)METHYL)AMINO)BENZOYL)AMINO)-2-CARBOXYETHYL)PHENOXY)-3-(2-(1,3-DIHYDRO-3,3-DIMETHYL-5-SULFO-1-(4-SULFOBUTYL)-2H-INDOL-2-YLIDENE)ETHYLIDENE)-1-CYCLOHEXEN-1-YL)ETHENYL)-3,3-DIMETH

Preferred Name

English

PAFOLACIANINE SODIUM [USAN]

Common Name

English

OTL38 TETRASODIUM

Code

English

CYTALUX

Brand Name

English

OTL0038 TETRASODIUM

Code

English

Pafolacianine tetrasodium

Common Name

English

OTL-0038 TETRASODIUM

Code

English

Pafolacianine tetrasodium [WHO-DD]

Common Name

English

OTL-38 TETRASODIUM

Code

English

2-(2-(2-(4-((2S)-2-(4-(((2-AMINO-4-OXO-3,4-DIHYDROPTERIDIN-6-YL)METHYL)AMINO)BENZAMIDO)-2-CARBOXYETHYL)PHENOXY)-3-(2-(3,3-DIMETHYL-5-SULFO-1-(4-SULFOBUTYL)-1,3-DIHYDRO-2H-INDOL-2-YLIDENE)ETHYLIDENE)CYCLOHEX-1-EN-1-YL)ETHENYL)-3,3-DIMETHYL-5-SULFO-1-(4-SU

Systematic Name

English

Code System Code Type Description

CAS

1628858-03-6